LED Medical Diagnostics Inc LEDIF

LMD - POLAR ASSET MANAGMENT HOLD OVER 17% OF LMD SHARES

[Kimsamkes]

REQUIRED DISCLOSURE BY AN ELIGIBLE INSTITUTIONAL INVESTOR UNDER PART 

ITEM 1 – SECURITY AND REPORTING ISSUER

1. 1.1  State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.

   Common shares (the “Shares”) of LED Medical Diagnostics Inc. (the “Issuer”), 580 Hornby Street, Suite 810, Vancouver, British Columbia, V6C 3B6.

2. 1.2  State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.

   TSX Venture Exchange.

ITEM 2 – IDENTITY OF THE ELIGIBLE INSTITUTIONAL INVESTOR

1. 2.1  State the name and address of the eligible institutional investor.

   Polar Asset Management Partners Inc. (“Polar”) 401 Bay Street, Suite 1900
   Toronto, Ontario
   M5H 2Y4 
    

   ITEM 3 – INTEREST IN SECURITIES OF THE REPORTING ISSUER

   1. 3.1  State the designation and the net increase or decrease in the number or principal amount of securities, and in the eligible institutional investor’s securityholding percentage in the class of securities, since the last report filed by the eligible institutional investor under Part 4 or the early warning requirements.

      Since the last report dated March 10, 2017, there has been a net increase of 13,333,334 Shares over which Polar, on behalf of client accounts over which it has discretionary trading authority, exercised control or direction, representing a net increase of 3.38% of all outstanding Shares.

   2. 3.2  State the designation and number or principal amount of securities and the eligible institutional investor’s securityholding percentage in the class of securities at the end of the month for which the report is made.

      As at August 31, 2017, Polar, on behalf of client accounts over which it has discretionary trading authority, exercised control or direction over 50,000,000 Shares and 18,333,333 warrants (each whole warrant being exercisable for a period of 24 months into one Share at a price of $0.10 per Share), representing approximately 17.42% of the issued and outstanding Shares (assuming conversion of any convertible securities into such Shares).

      The foregoing percentage was calculated based on 373,833,872 Shares outstanding as at August 16, 2017 pursuant to the information set out in the Issuer’s Management Discussion and Analysis for the three and six months ended June 30, 2017 dated as of August 16, 2017.